Axsome Therapeutics, Inc.AXSM
NasdaqGM•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $708.24M, growing 63.9% year-over-year. TTM net income stood at $-188.30M (32.3% growth). Quarterly EBITDA was $-63.36M and operating income was $-63.36M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze AXSM growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters